Selvigaltin is a small molecule commercialized by Galecto, with a leading Phase II program in Decompensated Cirrhosis. According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Selvigaltin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Selvigaltin is expected to reach an annual total of $15 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Selvigaltin Overview
Selvigaltin is under development for the treatment of liver cirrhosis, decompensated cirrhosis (Child-Pugh B), metastatic melanoma, head and neck squamous cell carcinoma, non-alcoholic steatohepatitis and non-small cell lung cancer. The drug candidate is formulated as hard capsules administered through oral route. It acts by targeting galectin 3.
Galecto Overview
Galecto is a drug development company that includes the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include GB1211 – liver fibrosis, GB2064 – oncology and fabrosis, GB1211 – oncology: NSCLC, GB1211 – oncology: melanoma and HNSCC. The company partners with various biotechnology companies for its drug development activities. Galecto is headquartered in Copenhagen, Massachusetts, Denmark.
The operating loss of the company was US$39.9 million in FY2023, compared to an operating loss of US$61.2 million in FY2022. The net loss of the company was US$38.4 million in FY2023, compared to a net loss of US$61.6 million in FY2022.
For a complete picture of Selvigaltin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
